{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:17:56Z","timestamp":1788135476537,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd014497","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"reference-count":90,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014497.pub2","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:42:57Z","timestamp":1754044977000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor necrosis factor-alpha antagonists for treatment of pediatric Crohn\u2019s disease"],"prefix":"10.1002","volume":"2025","author":[{"given":"Andrea","family":"Sep\u00falveda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nutrition, Division of Pediatrics, School of Medicine; Pontificia Universidad Cat\u00f3lica de Chile; Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"de la Piedra Bustamante","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nutrition, Division of Pediatrics, School of Medicine; Pontificia Universidad Cat\u00f3lica de Chile; Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Orlanski-Meyer","sequence":"additional","affiliation":[{"name":"The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition; Shaare Zedek Medical Center; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A","family":"Villarroel del Pino","sequence":"additional","affiliation":[{"name":"School of Public Health; Faculty of Medicine, Pontificia Universidad Cat\u00f3lica de Chile; Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Olivares Labbe","sequence":"additional","affiliation":[{"name":"Bibliotecas UC; Pontificia Universidad Cat\u00f3lica de Chile; Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Crist\u00f3bal","family":"Gana","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nutrition, Division of Pediatrics, School of Medicine; Pontificia Universidad Cat\u00f3lica de Chile; Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ibd.21349","article-title":"Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends","volume":"17","author":"Benchimol","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0002|cit2","first-page":"S9","article-title":"Inflammatory bowel disease: the difference between children and adults","volume":"14 Suppl 2","author":"Kelsen","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1002\/14651858.CD014497.pub2-BIB0003|cit3","first-page":"619","article-title":"Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007-2016","volume":"26","author":"Ye","year":"2020","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ibd.21152","article-title":"Natural history of Crohn's disease: comparison between childhood- and adult-onset disease","volume":"16","author":"Pigneur","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ibd.20378","article-title":"Guidelines for the management of growth failure in childhood inflammatory bowel disease","volume":"14","author":"Heuschkel","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/MPG.0000000000001177","article-title":"Growth pattern in paediatric Crohn disease is related to inflammatory status","volume":"63","author":"Ley","year":"2016","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"10","key":"10.1002\/14651858.CD014497.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease","volume":"8","author":"Ruemmele","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.cgh.2013.11.005","article-title":"Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease","volume":"12","author":"Bouguen","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn's disease digestive damage score, the Lemann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","article-title":"Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health","volume":"61","author":"Peyrin-Biroulet","year":"2012","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD014497.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"American Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD014497.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.crohns.2014.02.021","article-title":"Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases","volume":"8","author":"Sandborn","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"issue":"8","key":"10.1002\/14651858.CD014497.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/MIB.0000000000001176","article-title":"Mucosal healing in clinical practice: a single-center pediatric IBD experience","volume":"23","author":"Santha","year":"2017","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cgh.2013.07.022","article-title":"Histologic remission: the ultimate therapeutic goal in ulcerative colitis?","volume":"12","author":"Peyrin-Biroulet","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gut.26.2.146","article-title":"Prognosis in Crohn's disease - based on results from a regional patient group from the county of Copenhagen","volume":"26","author":"Binder","year":"1985","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD014497.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/j.gastro.2008.06.079","article-title":"Natural history of pediatric Crohn's disease: a population-based cohort study","volume":"135","author":"Vernier-Massouille","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ibd.23004","article-title":"Long-term outcome after first intestinal resection in pediatric-onset Crohn's disease: a population-based study","volume":"19","author":"Boualit","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Kugathasan S Denson LA Walters TD Kim MO Marigorta UM Schirmer M Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study Lancet 2017 389 10080 1710 8 10.1016\/S0140-6736(17)30317-3","DOI":"10.1016\/S0140-6736(17)30317-3"},{"issue":"4","key":"10.1002\/14651858.CD014497.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn's disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"issue":"12","key":"10.1002\/14651858.CD014497.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","article-title":"Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study","volume":"5","author":"Solberg","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"15","key":"10.1002\/14651858.CD014497.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD014497.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"9613","key":"10.1002\/14651858.CD014497.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0024|cit24","first-page":"3","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn's disease","volume":"11","author":"Gomollon","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"issue":"8785","key":"10.1002\/14651858.CD014497.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"issue":"9317","key":"10.1002\/14651858.CD014497.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4291\/wjgp.v6.i2.33","article-title":"Current therapy of pediatric Crohn's disease","volume":"6","author":"Lahad","year":"2015","journal-title":"World Journal of Gastrointestinal Pathophysiology"},{"issue":"4","key":"10.1002\/14651858.CD014497.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease","volume":"98","author":"Baldassano","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD014497.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","article-title":"Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study","volume":"21","author":"Sharma","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"issue":"8","key":"10.1002\/14651858.CD014497.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5","key":"10.1002\/14651858.CD014497.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD014497.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cgh.2006.04.022","article-title":"Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Rutgeerts","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease","volume":"50","author":"Ten Hove","year":"2002","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD014497.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014497.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD014497.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD014497.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD014497.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate-to-severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD014497.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10620-009-0791-7","article-title":"Adalimumab treatment in children with refractory Crohn's disease","volume":"55","author":"Rosenbach","year":"2010","journal-title":"Digestive Diseases and Sciences"},{"issue":"12","key":"10.1002\/14651858.CD014497.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/ajg.2009.493","article-title":"Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease","volume":"104","author":"Rosh","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD014497.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2036.2011.04603.x","article-title":"A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease","volume":"33","author":"Russell","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD014497.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/ecco-jcc\/jjy087","article-title":"Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn's disease: results from IMAgINE 1 and IMAgINE 2","volume":"12","author":"Ruemmele","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0051|cit51","first-page":"171\u201394","article-title":"The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update","volume":"15","author":"Rheenen","year":"2021","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5. Art. No.: CD","key":"10.1002\/14651858.CD014497.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014497","article-title":"Tumour necrosis factor-alpha antagonists for treatment of paediatric Crohn\u2019s disease","author":"Gana","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0053|cit53","unstructured":"Higgins JPT Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews London Cochrane"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD014497.pub2-BIB0055|cit55","first-page":"439","article-title":"Development and validation of a pediatric Crohn's disease activity index","volume":"12","author":"Hyams","year":"1991","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0056|cit56","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"4","key":"10.1002\/14651858.CD014497.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0058|cit58","unstructured":"Higgins JP Churchill R Chandler J Cumpston MS Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0059|cit59","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19 Suppl A","author":"Silverberg","year":"2005","journal-title":"Journal Canadien de Gastroenterologie"},{"issue":"5","key":"10.1002\/14651858.CD014497.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"9128","key":"10.1002\/14651858.CD014497.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD014497.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"7644","key":"10.1002\/14651858.CD014497.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"6","key":"10.1002\/14651858.CD014497.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"35","key":"10.1002\/14651858.CD014497.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"5","key":"10.1002\/14651858.CD014497.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: the ROBES Meta-Epidemiologic study","volume":"187","author":"Savovic","year":"2018","journal-title":"American Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD014497.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014497.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"11","key":"10.1002\/14651858.CD014497.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD014497.pub2-BIB0072|cit72","first-page":"557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7454","key":"10.1002\/14651858.CD014497.pub2-BIB0073|cit73","first-page":"1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0074|cit74","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0075|cit75","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2021"},{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut"},{"issue":"138","key":"10.1002\/14651858.CD014497.pub2-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1097\/mpg.0000000000003823","article-title":"Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to severe Crohn's disease - an update from the TISKids study","volume":"76.0","author":"Cozijnsen","year":"2023","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"e000123","DOI":"10.1136\/bmjgast-2016-000123","article-title":"Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial","volume":"3","author":"Cozijnsen","year":"2016","journal-title":"BMJ Open Gastroenterology"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ibd.21836","article-title":"Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial","volume":"18","author":"Rubin","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1002\/14651858.CD014497.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"issue":"09","key":"10.1002\/14651858.CD014497.pub2-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2013.09.003","article-title":"A comparative study of induction of remission and cost-effectiveness of enteral nutrition versus infliximab in moderate-to-severe Crohn's disease","volume":"52","author":"Zhu","year":"2013","journal-title":"Chinese Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0082|cit82","unstructured":"AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA MULTICENTER COMPARATIVE STUDY BETWEEN NUTRITIONAL THERAPY ALONE AND ANTI-TNF-alpha MONOCLONAL ANTIBODY IN INDUCING AND MAINTAINING REMISSION IN PEDIATRIC CROHN`S DISEASE: a RANDOMIZED CONTROLLED TRIAL EU Clinical Trials Register"},{"issue":"11","key":"10.1002\/14651858.CD014497.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1586\/1744666X.2014.955017","article-title":"Biologics in pediatric Crohn's disease: is it time to move to an earlier therapeutic approach?","volume":"10","author":"Hyams","year":"2014","journal-title":"Expert Review of Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study","volume":"63","author":"Valk","year":"2014","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD014497.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn's disease","volume":"52","author":"Qiu","year":"2017","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD014497.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD014497.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1651-2227.2010.01938.x","article-title":"Infliximab therapy in children with Crohn's disease: A one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies","volume":"100","author":"Kim","year":"2011","journal-title":"Acta Paediatrica, International Journal of Paediatrics"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"3813915","DOI":"10.1155\/2022\/3813915","article-title":"Outcomes of pediatric patients with Crohn's disease received infliximab or exclusive enteral nutrition during induction remission","volume":"-","author":"Lv","year":"2022","journal-title":"Gastroenterology Research and Practice"},{"issue":"8","key":"10.1002\/14651858.CD014497.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1097\/MIB.0000000000000426","article-title":"Comparative effectiveness of nutritional and biological therapy in North American children with active Crohn's disease","volume":"21","author":"Lee","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD014497.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"6595048","DOI":"10.1155\/2017\/6595048","article-title":"Exclusive enteral nutrition versus infliximab in inducing therapy of pediatric Crohn's disease","volume":"-","author":"Luo","year":"2017","journal-title":"Gastroenterology Research and Practice"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:03:43Z","timestamp":1788134623000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014497.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":90,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014497.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}